Source Report

**NNE's cash position exploded to $577.5 million as of December 31, 2025, via a mechanism where an oversubscribed private placement priced shares at a $47.11 premium ($400 million gross, $379 million net from 8.49 million new shares), extending runway dramatically despite a modest $4 million quarterly operating burn—management affirms liquidity covers at least 12 months amid rising R&D for KRONOS MMR™ prototypes, but pre-revenue status implies reliance on further raises.[1][2][3]
- Cash & equivalents: $577.5M (Dec 31, 2025) vs. $203.3M (Sep 30, 2025), per Q1 FY2026 10-Q filed Feb 17, 2026[1]
- Quarterly operating cash use: $4.0M (three months ended Dec 31, 2025), up slightly YoY on ops/R&D ramp for KRONOS MMR™[3]
- Net loss: $6.5M for quarter; working capital: $576M[2]

For entrants eyeing nuclear microreactors, NNE's cash fortress funds $300-350M prototype builds without immediate distress sales, but watch for ATM activation as burn scales with licensing/site work—non-obvious edge is institutional buy-in signaling validation, though dilution has already hiked shares 40%+ YoY.

Recent Capital Raises: Serial Dilutive Equity Fuels Growth

**Nano Nuclear Energy has raised over $600 million since May 2024 IPO via layered private placements and offerings, with the October 2025 deal (8.49M shares at $47.11) exemplifying how premium pricing from institutional demand minimizes per-share pain while ballooning the balance sheet—yet each tranche dilutes ~20% quarterly, eroding retail stakes as shares outstanding jumped from 41.7M (Sep 2025) to 52.1M (Feb 2026).[1][3]
- Oct 2025 PIPE: $400M gross/$379M net (8.49M shares); prior May 2025 PIPE: $105M gross/$99M net (3.89M shares); Nov 2024 PIPE: $60M gross/$55M net (2.5M shares)[1]
- Earlier 2024 public/follow-on offerings: ~$65M gross[1]
- Active $900M shelf (incl. $400M ATM via TD Cowen/UBS/Piper Sandler, filed ~July 2025, active 2026) enables opportunistic dilution at market prices[4][5]

Competitors must match this access: NNE's proven institutional pipeline lowers cost of capital, but ATM/shelf flags high dilution risk—~21% share increase in Q1 alone means entrants need derisked tech to avoid fire sales.

Key Financial Metrics	Value (USD, as of/reporting date)	Source/Notes
Cash & Equivalents	$577.5M (Dec 31, 2025)[1]	Q1 10-Q; post-Oct PIPE
Quarterly Burn (Ops Cash Use)	$4.0M (Q1 FY2026)[3]	Slight YoY increase on R&D
Shares Outstanding	52.08M (latest est. Mar 2026); 52.08M (Feb 16, 2026); 50.58M (Dec 31, 2025)[6][2]	Post-warrant exercises
Insider Ownership	18.71%-32.77% (var. sources; e.g., Jiang Yu ~9.8M shares)[6][7]	Recent sales: 3.98M shares ($126M) past 90 days[8]
Institutional Ownership	50.03%-51% (~26M shares; 229 funds)[9][6]	Top: Van Eck (6.25%), BlackRock (5.4%), Vanguard; +28% shares MRQ[9]
Working Capital	$576M (Dec 31, 2025)[1]	Sufficient for 12+ months
Total Equity	$600M (Dec 31, 2025)[1]	Post-raise

Dilution flagged: +40% shares YoY; $900M shelf/$400M ATM enables rapid funding but could add 20M+ shares at current ~$21 price—insiders trimmed amid volatility, signaling profit-taking post-rallies.[10] New entrants: Avoid unless tech moat justifies similar institutional tolerance for 20%+ annual dilution.

Ownership: Institutions Dominate, Insiders Trim

**Institutions control ~50% (26M shares across 229 holders), drawn by nuclear tailwinds—Van Eck's 6.25% stake (via Q3 2025 13F adds) reflects ETF/nuclear thematic bets, while insiders (~19-33%, led by Chairman Yu at ~19%) sold $126M (4M shares) in 90 days, cashing gains without full exit (still ~9.8M shares held).[9][11]
- Inst. inflows: $424M past 12 months (141 buyers vs. 35 sellers)[12]
- Recent 13Fs (Q1 2026): Van Eck +24.7%, Invesco +53%; some trims (Virtu -70%)[12]

For competitors: NNE's 50% inst. float locks in support for long-haul R&D, but insider sales post-raise flag valuation caution—aim for <10% insider churn to build trust.

Milestones & Revenue: Pre-Revenue to 2030+ Commercial

**NNE targets KRONOS MMR™ prototype ops ~2030 via NRC Part 50 permit (submit H1 2026, construct mid-2027), leveraging acquired assets/site work at U. Illinois—near-term revenue pivots to HALEU transport (2027-28) and consulting (2026), but zero material sales since inception means milestones hinge on regulatory wins, not cash flow.[3][1]
- Fuel transport: Launch 2028; fuel fab: 2027 near INL[1]
- Analysts proj. <$10M FY2026 revenue to $4B FY2037 (73% CAGR), but unverified/estimated[13]

Implication for space: Execution risk high—delays push dilution; entrants prioritize aux revenue (transport/consult) for self-funding vs. NNE's burn-to-breakthrough model.

---

Recent Findings Supplement (March 2026)

Recent Capital Infusion Bolsters Runway Amid Pre-Revenue Development

Nano Nuclear Energy (NNE) dramatically strengthened its balance sheet via an oversubscribed $400 million private placement of 8.49 million common shares in October 2025, netting ~$379 million after fees; this mechanism—priced at market under Nasdaq rules—directly funded KRONOS MMR microreactor prototyping ($300-350 million estimated per unit) and fuel supply chain advances, extending cash runway to over 20 years at current burn while enabling parallel U.S./Canada licensing tracks without immediate debt reliance.[1]
- Q1 FY2026 (ended Dec 31, 2025) cash: $577.5 million, up from $203.3 million at FY2025-end (Sep 30, 2025)[2]
- Cash flows: Operating use $4.0 million; investing use $3.1 million (e.g., Oak Brook facility); financing provide $381.3 million[1]
- Net loss $6.5 million (op loss $11.6 million on ~$8 million higher expenses vs prior year); interest income ~$5 million offset losses[2]
For competitors or entrants, this data moat (real-time sales visibility absent in traditional nuclear) funds de-risking via prototype builds, but signals reliance on equity markets—new players must match via grants or partnerships to avoid cost disadvantages.

ATM Shelf Flags Heightened Dilution Exposure

NNE filed a $900 million S-3 shelf in March 2026, including a $400 million ATM program via TD Cowen/UBS/Piper Sandler, explicitly to scale KRONOS amid prototype capex; shares sold at market prices dilute existing holders immediately (pro forma net tangible book value rises modestly to $14.29/share from $11.79), with ~5.5 million potential new shares at recent $23.54 price, exacerbating post-raise overhang from the 8.49 million PIPE shares now resale-registered.[3]
- Shares outstanding: 50.58 million (Dec 31, 2025); 52.08 million (Mar 6, 2026); float ~34.9 million[3]
- Additional dilution vectors: 3.0 million warrants/options/RSUs exercisable[3]
- Recent insider sales: ~4 million shares ($126 million) past 90 days (e.g., Chairman Yu 767k at $34.14), ownership steady at 32.77%[4]
Entrants face ATM as double-edged: accelerates funding without lockups but erodes EPS; compete by proving lower capex (e.g., via DoE grants) to minimize shelf dependency.

Ownership Stable Despite Sales, Institutions Building Stakes

Insiders hold 32.77% post-sales (Chairman Yu ~8.72 million shares), signaling alignment amid ~$126 million divestitures; institutions own ~50% (up 28% shares MRQ to 26 million), with Q4 2025 13Fs showing Van Eck (5.17%, +66%), Vanguard (+41%), BlackRock adds—mechanism leverages post-PIPE visibility for index inclusion (e.g., Morgan Stanley National Security).[5][4]
- Top holders: Van Eck (2.60 million), BlackRock, Vanguard (1.78 million), Mirae, Weiss[5]
- 229 institutions (216 long), avg portfolio 0.05%[5]
New entrants benchmark ~33% insider stake for credibility; institutions favor NNE's fuel/transport near-term over pure reactor plays—replicate via Q1F filings transparency.

Modest Burn Supports Multi-Year Milestones, No Near-Term Revenue

Q1 cash burn ~$7.1 million ($4M op + $3.1M inv) implies ~$28 million annualized (~5% of cash), yielding 20+ year runway; pre-revenue status persists, but HALEU transport (Advanced Fuel Transportation) eyes 2027-2028 logistics revenue, KRONOS prototype mid-2027 (NRC Part 50 permit soon), full commercialization ~2030—mechanism auto-deducts from future ops like Shopify Capital, but nuclear reg delays common.[6][1]
- Milestones: UIUC MOU (prototype site), $6.8M REV grant, NRC topical approvals, UAE/S. Korea MOUs[2]
- No updated FY2026 guidance; FY2025 loss ~$40 million (prior)[6]
Competitors enter via fuel/transport (shorter timeline) over reactors; NNE's burn discipline (interest offsets) sets bar—watch Q2 for permit filing.

Key Metric	Value (Q1 FY2026, Dec 31 2025)	Prior (FY2025-end)	Notes
Cash & Equiv.	$577.5M[2]	$203.3M	Post-$379M net PIPE[1]
Shares Outstd.	50.58M (Dec 31); 52.08M (Mar 6)[3]	N/A	+8.49M from PIPE
Q Burn (Op+Inv)	$7.1M	~$6M (prior Q)	Runway 20+ yrs[6]
Net Loss	$6.5M	$3.5M	Pre-revenue[2]
Insider Own.	32.77%[4]	Stable	Post-$126M sales
Inst. Own.	~50%[5]	+28% shares	Van Eck leads

Dilution Risks (High Confidence): $400M ATM + $500M shelf remainder enables rapid raises at market (recent $21-23), potentially adding 20M+ shares; prior PIPE resale + insider sales pressure price; limited auth shares (275M) may force votes. No 13F totals post-Q4 2025, but trend upward—additional research via EDGAR Q1 13Fs strengthens. Revenue timelines unverified beyond guidance (est. 2027-28 HALEU).[3]